Skip to content

DermoLab

Active Private limited companyfounded 2022active for 3 yearsHeiken 16, 2290 VorselaarKBO/BCE: BE 0794.830.866

Lifetime

3 annual accounts with figures on one time axis
peak of €204,258 in 2025
€204,258▲ 77.5%
peak of €143,899 in 2025
€143,899▲ 83.1%
peak of €121,606 in 2024
€121,606unchanged
€161,491▲ 572%
Board2 names since 2022
2 directors and 1 other
Documentsfilings and deeds
13-02-2026168 days before the deadline
2025micro format
Gross margin from €115,059 to €204,258Result from €78,601 to €143,899Dividend €143,899Debts from €24,032 to €161,491Cash from €122,469 to €55,512

Key points

from the 2025 annual accounts

Equity

€121,606 =
121,6062024+143,899Profit-143,899Dividend121,6062025

DermoLab paid out €143,899 in dividends. That is 100% of the 2025 profit.

Result

€143,899 ▲ 83.1%
€78,6002024€144,0002025

The result rose in 2025 from €78,601 to €143,899.

Turnover

≈ €380,000 estimated

The micro format states no turnover.

Debts

€161,491 ▲ 572%
Other debts
+137,609
Suppliers
+5,482
The rest
-5,632

Debts rose by €137,459 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Investments

€6,713 1.7 times depreciation
202320242025

Green is investment, beige is depreciation.

Liquidity

1.68 was 5.71 in 2024

Short-term debts rose from €24,032 to €161,491.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,329 companies had the same profile as DermoLab has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,329 companies, not a prediction for DermoLab. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • 100 sharesdeed of 19-12-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0794830866
Incorporation Founding capital of €2,000, 100 shares · Founded by (comparant oprichter) · (statutory director) and (director) appointed · published on 19-12-2022 · Gazette deed
First establishment Heiken 16, Vorselaar
All 9 events

Comparable companies

same main activity, similar in size and age
Company
DermoLab Vorselaar €283,097 €204,258 43.0% -
Dokter Pauline Lemmens Antwerp €302,835 €198,702 78.2% -
Dr. Christophe De Laet Kontich €272,424 €219,779 83.7% -
Dr. Tijs Bringmans, cardioloog Sint-Katelijne-Waver €263,267 €190,711 71.6% -
Dr. Nelson Korir Anesthesie Wommelgem €257,837 €222,648 100.0% -
ANESTH ME Chaumont-Gistoux €270,210 €206,049 96.6% -
DR. GAETAN CLAEYS ANESTHESIE-INTENSIEVE ZORGEN Damme €269,662 €215,489 78.9% -

These companies have the same main activity as DermoLab: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €258,000 and €303,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 15-12-2022Normal situation
Activity
Specialist medical practiceNACE 86220and 3 others
Establishment unit
2.339.591.1042290 Vorselaar, since 15-12-2022
Financial year end
31 December
Peppol
Reachable since 07-12-2025
Company details

Annual accounts 2025

€283,097▲ 94.4%
Filing
Filed on 13-02-2026, 168 days before the end of the filing period
Financials

Insights on DermoLab

DermoLab files the micro format. That format states no turnover. The gross margin rose from €61,345 in 2023 to €204,258 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DermoLab

What is the company number of DermoLab?
The company number of DermoLab is 0794.830.866. The VAT number is the same number with BE in front: BE 0794.830.866.
Where is DermoLab based?
The registered office is at Heiken 16, 2290 Vorselaar.Company details
What does DermoLab do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of DermoLab?
DermoLab is a private limited company (BV).
When was DermoLab founded?
DermoLab was founded on 15-12-2022.
Is DermoLab still active?
Yes, DermoLab is an active enterprise in the KBO register.
What is the turnover of DermoLab?
The turnover in financial year 2025 is ≈ €380,000. This figure is estimated from the gross margin of €204,258 and 40 comparable companies (NACE 86220). It probably lies between €320,000 and €510,000.Financials
Is DermoLab profitable?
In financial year 2025, DermoLab made a profit of €143,899.
Where can I find the annual accounts of DermoLab?
DermoLab filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DermoLab due?
DermoLab must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.